Clinical Trials Sponsored by Curesponse Ltd.

Total 16962 results

Imperial College London
Curesponse Ltd.

Not yet recruiting

Prediction of Drug Response Using an Ex Vivo Organ Culture (EVOC) on Fresh Human Tumour Samples From Metastatic Patients (CURESPONSE)

Metastatic Cancer | Advanced Cancer
Response Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's Disease

Raynaud's Disease

Germany
Response Pharmaceuticals

Completed

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

Drug-induced Weight Gain

United States
Response Pharmaceuticals

Completed

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Response Biomedical Corp.

Completed

FLU A+B Nasal Swab Clinical Study (FLUA+B)

Influenza

United States, Canada
Response Biomedical Corp.

Completed

RAMP 200 / RAMP Cardiovascular Tests at the Point-of-Care (C-POC)

Myocardial Infarction | Heart Failure | Acute Coronary Syndrome | Congestive Heart Failure

United States
Response Pharmaceuticals

Completed

Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension

Hypertension

Germany
Response Pharmaceuticals

Completed

A Comparison of SLx-4090 in Combination With Metformin Versus Metformin Therapy Alone in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Response Pharmaceuticals

Completed

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

Hyperlipidemia

United States
Response Pharmaceuticals

Completed

Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

Hypertriglyceridemia

Germany
Response Pharmaceuticals

Completed

Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension

Hypertension

United Kingdom
Immune Response BioPharma, Inc.

Not yet recruiting

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

Multiple Sclerosis

United States
Immune Response BioPharma, Inc.

Unknown

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

HIV/AIDS

United States
Response Biomedical Corp.

Terminated

Beta-hCG Test Reference Range Determination

Healthy

Canada
Response Biomedical Corp.

Completed

Procalcitonin Test Reference Range Determination (PRO-H)

Healthy

Canada
Immune Response BioPharma, Inc.
cro

Unknown

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis

United States
Immune Response BioPharma, Inc.

Unknown

REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study (RAISE)

HIV

United States
Immune Response BioPharma, Inc.
cro

Recruiting

A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis | Secondary Progress Multiple Sclerosis

United States
Irish Response t/a Lifes2good
Stephens & Associates, Inc.

Completed

To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair

Hair Thinning

United States
The Immune Response Corporation

Completed

An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml

HIV Infections

United States
The Immune Response Corporation

Completed

A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega

HIV Infections

United States
Ablon Skin Institute Research Center
Irish Response t/a Lifes2good

Completed

Viviscal Extra-Strength Formulation To Promote Hair Growth And Decrease Shedding In Women With Thinning Hair

Hair Thinning
The Immune Response Corporation

Completed

An Expanded Access Open Label Protocol of Remune (HIV-1 Immunogen) in HIV-1-Infected Adults With CD4 Count 550 Cells /Ml and Greater.

HIV Infections

United States
Mirka Ltd
Clinius Ltd

Completed

A Pre-market Study to Evaluate the Performance and Safety of a Skin Preparation Device for Removal of Dry Crusty Skin

Keratosis, Actinic | Hyperkeratotic Callus | Actinic Lesion | Solar Keratosis/Sunburn | Hyperkeratosis | Hyperkeratotic; Lesion | Hyperkeratotic Actinic Keratosis

Finland
Salus Ltd.
TheraVitae Ltd.

Completed

Autologous Angiogenic Cell Precursors (ACPs) for the Treatment of Peripheral Artery Disease

Critical Limb Ischemia

Hungary
Janssen-Cilag Farmaceutica Ltda.
Janssen Korea, Ltd., Korea

No longer available

An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes

Hong Kong, Brazil, Thailand
Ablon Skin Institute Research Center
DeNova Research; Irish Response t/a Lifes2good

Completed

Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair

Hair Thinning
National Institute of Allergy and Infectious Diseases...
The Immune Response Corporation

Terminated

Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination

HIV Infections

United States
Paion UK Ltd.
Chiltern International Ltd.; HFL Ltd.

Completed

An Efficacy and Safety Study to Compare Morphine 6-glucuronide (M6G) and Morphine in Patients Suffering With Post-Operative Pain for at Least 24 Hours

Postoperative Pain

France, Germany, Netherlands, Poland, United Kingdom, Czechia
Calcivis Ltd
Medsource UK Ltd.

Completed

Caries Lesion Activity in Orthodontic Patients - Calcivis System

Dental Caries

United Kingdom
Cardiovalve Ltd.
Meditrial Europe Ltd.

Recruiting

Cardiovalve Transfemoral System - FIM Study

Mitral Regurgitation

Lithuania
Vensica Therapeutics Ltd.
Blueclinical, Ltd.

Completed

Clinical Trial for the Assessment of Safety, Usability and Efficacy of the Vixe Combination for OAB in Female Subjects (XAVIER)

Overactive Bladder

Portugal
Nanomedic Technologies Ltd.

Completed

Evaluation of the SpinCare™ System in the Treatment of Partial Thickness Burns (SPINCARE2)

Partial Thickness Burn

Israel
Nanomedic Technologies Ltd.

Completed

Evaluation of the SPINNER Device for the Application of Wound Dressing: Treatment of Split Skin Graft Donor Sites (SPINNER01)

Wound of Skin

Israel
Danisco
4Pharma Ltd.; Medfiles Ltd.

Completed

Next Generation Probiotics (NGPs) for Metabolic Health

Microbial Colonization
Calcivis Ltd
Medsource UK Ltd.

Completed

Safety and Performance Evaluation of the Calcivis System

Dental Caries

United Kingdom
Targia Pharmaceuticals Ltd.
SoluBest Ltd.

Unknown

Comparative Bioavailability Study of Omexa Sumatriptan vs. Imitrex® in Healthy Volunteers

Migraine
Xention Ltd
Ario Pharma Ltd

Completed

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD

Chronic Obstructive Pulmonary Disease

United Kingdom
TyrNovo Ltd.

Active, not recruiting

A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck | Metastatic Solid Tumor | Colorectal Adenocarcinoma | Solid Tumor, Adult | Recurrent Solid Tumor

United States, Israel
Xention Ltd
Ario Pharma Ltd

Completed

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough

Chronic Idiopathic Cough

United Kingdom, Ireland
Neurovalens Ltd.
University College Dublin; Exploristics Ltd; Compliance Solutions Ltd.

Completed

Effect of VeSTAL Device in Type 2 Diabetes Mellitus

Metabolic Syndrome | Type 2 Diabetes

Ireland
Neurovalens Ltd.
University College Dublin; Exploristics Ltd; Compliance Solutions Ltd.

Completed

Electrical Vestibular Nerve Stimulation (VeNS) Compared to Sham Control as a Means of Reducing Excess Body Weight

Obesity | Overweight | Metabolic Syndrome | Overweight and Obesity | Overweight or Obesity

Ireland
Nemysis Ltd
RDC Clinical Pty Ltd

Recruiting

Safety and Effectiveness of Iron Hydroxide Adipate Tartrate (IHAT) in Iron Deficient Premenopausal Women

Iron-deficiency

Australia
Nuritas Ltd
RDC Clinical Pty Ltd

Recruiting

Effects of PeptiSleep in Healthy Males and Females With Mild to Moderate Sleep Impairment

Sleep

Australia
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (AERO-PD)

Asthma

Greece
Akaza Bioscience Ltd
Iqvia Pty Ltd

Not yet recruiting

TAK-242 in Patients With Acute Alcoholic Hepatitis

Acute-On-Chronic Liver Failure
Persica Pharmaceuticals Ltd
Micron Research Ltd

Active, not recruiting

Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain

Chronic Low-back Pain

Spain, United Kingdom, New Zealand, Denmark
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma (ANASSA-PD)

Asthma

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pilot Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece

3

Subscribe